ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Beijing Biotech, AstraZeneca and Daiichi Sankyo side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Beijing Biotech×AstraZeneca×Daiichi Sankyo×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Beijing BiotechAstraZenecaDaiichi Sankyo
studies on the registry324,197499
open to participants now3229837
phase 3 studies under way020021
reach primary completion within a year3116811
programswith a study of their own in two years40119+5 named only20

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBeijing BiotechAstraZenecaDaiichi Sankyo
Phase 1

Beijing Biotech: 1 of its 40 programs at phase 1

  1. ETB-DualNK-01phase 1
3%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Daiichi Sankyo: 7 of its 20 programs at phase 1

  1. DS1025Aphase 1
  2. DS3610Aphase 1
  3. DS5361Bphase 1
  4. DS9051Bphase 1
  5. valemetostatphase 1

and 2 more — sign in to see them all

35%
Phase 2

Beijing Biotech: 39 of its 40 programs at phase 2

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2
  3. Dual-target CAR-NK cellsphase 2
  4. ebnk-1822h2 dual-target cldn18.2phase 2
  5. Lymphodepleting chemotherapyphase 2

and 34 more — sign in to see them all

98%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
25%
Phase 300%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Daiichi Sankyo: 4 of its 20 programs at phase 3

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. raludotatug deruxtecanphase 3
20%
Approved, new studies00%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Daiichi Sankyo: 4 of its 20 programs at approved, new studies

  1. quizartinibapproved, new study
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study
20%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Beijing Biotech40 readouts · 0 phase 3···

Beijing Biotech, Feb ’27: 11 programs whose next study reaches primary completion

  1. Dual-target CAR-NK cellsphase 2 · Feb 14 · NCT07467863
  2. Dual-target CAR-NK cells (EB-DT-CAR-NK)phase 2 · Feb 14 · NCT07486089
  3. EB-DART-NK01phase 2 · Feb 14 · NCT07744256
  4. EB-DART-NK01 (DLL3/CD56 CAR-NK cells)phase 2 · Feb 14 · NCT07480213
  5. EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)phase 2 · Feb 14 · NCT07480928

and 6 more — sign in to see them all

Beijing Biotech, Mar ’27: 21 programs whose next study reaches primary completion

  1. Autologous Anti-CD19 CAR-expressing T Lymphocytesphase 2 · Mar 14 · NCT07523542
  2. Autologous BCMA/CD19 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  3. Autologous BCMA/CD38 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  4. Autologous BCMA/GPRC5D dual-target CAR-Tphase 2 · Mar 14 · NCT07523555
  5. Autologous CD19/CD20 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555

and 16 more — sign in to see them all

Beijing Biotech, Apr ’27: 3 programs whose next study reaches primary completion

  1. Autologous dual-target CAR-T cells selected from the predefined target library.phase 2 · Apr 14 · NCT07523529
  2. eb-701phase 2 · Apr 14 · NCT07551349
  3. EB-701/CA9-NKphase 2 · Apr 14 · NCT07551349
·

Beijing Biotech, Jun ’27: 5 programs whose next study reaches primary completion

  1. AP 1903 reagentphase 2 · Jun 14 · NCT07598955
  2. EB-CAR30-NKphase 2 · Jun 14 · NCT07598955
  3. EB-CAR5-NKphase 2 · Jun 14 · NCT07598955
  4. EB-CARMSLN-NKphase 2 · Jun 14 · NCT07598955
  5. EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cellsphase 2 · Jun 14 · NCT07627698
····
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Daiichi Sankyo3 readouts · 1 phase 3·

Daiichi Sankyo, Dec ’26: 1 program whose next study reaches primary completion

  1. raludotatug deruxtecanphase 3 · Dec 30 · NCT04707248
····

Daiichi Sankyo, May ’27: 1 program whose next study reaches primary completion

  1. quizartinibapproved, new study · May 1 · NCT03793478
····

Daiichi Sankyo, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trastuzumab deruxtecanphase 3 · Oct 1 · NCT05950945
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Beijing Biotech

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Daiichi Sankyo

New programs 1

  • olomorasibphase 2 · first study · Oct 16 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 37 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionBeijing BiotechAstraZenecaDaiichi Sankyo
Carcinoma, Non-Small-Cell Lungall three · compare here

Beijing Biotech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Cyclophosphamidephase 2
  2. Dual-target CAR-NK cellsphase 2

Their studies: Beijing Biotech’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsall three · compare here

Beijing Biotech in Prostatic Neoplasms: 2 programs

  1. AP 1903 reagentphase 2
  2. ETB-DualNK-01phase 1

Their studies: Beijing Biotech’s studies of Prostatic Neoplasms in search

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Daiichi Sankyo in Prostatic Neoplasms: 1 program

  1. valemetostatphase 1

Their studies: Daiichi Sankyo’s studies of Prostatic Neoplasms in search

Breast Neoplasmsall three · compare here

Beijing Biotech in Breast Neoplasms: 1 program

  1. Cyclophosphamidephase 2

Their studies: Beijing Biotech’s studies of Breast Neoplasms in search

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Daiichi Sankyo in Breast Neoplasms: 3 programs

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Breast Neoplasms in search

Neoplasmsall three · compare here

Beijing Biotech in Neoplasms: 4 programs

  1. Lymphodepleting chemotherapyphase 2
  2. Cytokine supportphase 2
  3. EB-PT-CAR-NK-Dphase 2
  4. EB-PT-CAR-NK-Sphase 2

Their studies: Beijing Biotech’s studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Daiichi Sankyo in Neoplasms: 1 program

  1. patritumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Neoplasms in search

Stomach Neoplasmsall three · compare here

Beijing Biotech in Stomach Neoplasms: 1 program

  1. EB-DT-CAR-NKphase 2

Their studies: Beijing Biotech’s studies of Stomach Neoplasms in search

Daiichi Sankyo in Stomach Neoplasms: 1 program

  1. trastuzumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Stomach Neoplasms in search

Neoplasm Metastasisall three · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Triple Negative Breast Neoplasmsall three · compare here

Beijing Biotech in Triple Negative Breast Neoplasms: 2 programs

  1. Dual-target CAR-NK cellsphase 2
  2. Dual-target CAR-NK cells (EB-DT-CAR-NK)phase 2

Their studies: Beijing Biotech’s studies of Triple Negative Breast Neoplasms in search

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Daiichi Sankyo in Triple Negative Breast Neoplasms: 1 program

  1. datopotamab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Triple Negative Breast Neoplasms in search

Hematologic Neoplasmsall three · compare here

Beijing Biotech in Hematologic Neoplasms: 1 program

  1. AP 1903 reagentphase 2

Their studies: Beijing Biotech’s studies of Hematologic Neoplasms in search

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

Daiichi Sankyo in Hematologic Neoplasms: 2 programs

  1. Anti-CD37/DXd Antibody-drug Conjugate DS3790phase 2
  2. Combination drugphase 2

Their studies: Daiichi Sankyo’s studies of Hematologic Neoplasms in search

Colorectal Neoplasmsall three · compare here

Beijing Biotech in Colorectal Neoplasms: 1 program

  1. EB-DUO-CAR-NK-CEA/GCCphase 2

Their studies: Beijing Biotech’s studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Daiichi Sankyo in Colorectal Neoplasms: 1 program

  1. olomorasibphase 2

Their studies: Daiichi Sankyo’s studies of Colorectal Neoplasms in search

Burkitt Lymphoma2 of 3 · compare here–
Renal Insufficiency2 of 3 · compare here–

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Daiichi Sankyo in Renal Insufficiency: 1 program

  1. olomorasibphase 2

Their studies: Daiichi Sankyo’s studies of Renal Insufficiency in search

Hyperlipidemias2 of 3 · compare here–

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

Daiichi Sankyo in Hyperlipidemias: 4 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Hyperlipidemias in search

Show all 37

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Beijing Biotech 1 of 40 · AstraZeneca 68 of 119 · Daiichi Sankyo 14 of 20 programs (41 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).